Neurological Diseases and Cancer - Area of concern for the Japanese Generic Drugs Manufacturers

Wednesday 3 October 2012, Amsterdam

The Japanese drug market is focusing massive generic penetration with a view to curb the prevalence of neurological diseases. Recent times have seen several key generic launches for neurological and behavioral disorders. As per findings of a latest research report, cancer-related generics are also expected be a highly promising area for growth and the number of global deals for cancer generics have been rising greatly. Promoting generics for cancer is also a major target area as the disease accounts for maximum healthcare-related expenditures for people below 65 years of age and promoting of generics in this segment would help cut expenditures.

Further, according to a recent report, "Japan Generics Market Analysis", cutting healthcare expenditure costs is the biggest concern for the government for which generics are being actively promoted in Japan's pharma market. The dispensing pharmacies have also been showing a trend of greater generic sales. International presence in the market has been growing as several global pharma leaders have shown interest in setting up generic manufacturing plants in Japan. Growing patent expirations are also a leading factor for the growth of generics.

Drug launches in the sector are robust and recent times have seen promising drug launches for neurological and behavioral disorders, diabetes, gastrointestinal problems and circulatory disorders in Japan. Backed by several promising factors, the Japanese generics market has shown positive developments over the past few years and is expected to grow at a CAGR of around 9% during 2012-2014.

The report provides an in-depth research and rational analysis of the current status and expected position of the Japanese generics market. It facilitates forecasts on overall pharmaceutical industry size and generics market for the period 2012-2014. The research evaluates and analyzes the opportunities for generic companies in Japan in terms of patent expiries and therapeutic areas to be tapped. Regulatory environment's overview and recent industry developments have also been included in the study to present a balanced outlook of the Japanese generic drugs market to clients.